Operational liquidity remains under pressure, with the firm burning $1.6 million in free cash flow during 2026Q1 and maintaining an OCF/NI ratio of -0.38.
| Cash from Operations | -11.45M | -13.39M | -14.23M | -22.51M | -10.39M | -10.98M | -10.43M | -6.77M |
| Operating CF Margin % | - | -24693.2% | -554.29% | -792.25% | -154.51% | - | -254.44% | - |
| Operating CF Growth % | 58.59% | 5.87% | 36.81% | -116.77% | 5.37% | -5.22% | -54.19% | - |
| Net Income | -1.63M | -7.96M | -30.02M | -24.99M | -14.9M | -12.86M | -5.8M | -7.29M |
| Depreciation & Amortization | 764.81K | 1.04M | 1.18M | 1.14M | 717.85K | 543.6K | 572.87K | 421.82K |
| Stock-Based Compensation | 297.51K | 768.62K | 1.01M | 1M | 1.12M | 360.98K | 21.88K | 1.76K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -8.57M | -4.46M | -418 | 4.98M | 188.46K | -473.22K | 23.04K | 0 |
| Working Capital Changes | -1.65M | -2.78M | 13.6M | -4.64M | 2.49M | 1.46M | -5.25M | 104.17K |
| Change in Receivables | 12.65K | 550.03K | 953.56K | -1.12M | -284.69K | 2.37M | -2.5M | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -2.42M | -3.47M | 11.87M | 1.62M | 418.21K | 1.89M | -628.65K | 766.39K |
| Cash from Investing | 0 | 0 | -261.62K | 3.8M | 14.71M | -35.02M | -186.68K | -1.46M |
| Capital Expenditures | 0 | 0 | -261.62K | -6.2M | -10.28M | -47.26K | -186.68K | -1.46M |
| CapEx % of Revenue | 0% | - | 10.19% | 218.26% | 152.86% | - | 4.55% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 164 |
| Cash from Financing | 11.57M | 10.67M | 15.57M | -14.53K | 6.27M | 49.27M | 11.72M | 13.45M |
| Debt Issued (Net) | -204.47K | 22.38K | 6.79M | -38.27K | 6.45M | 0 | 563.59K | 0 |
| Equity Issued (Net) | 8.25M | 11.86M | 6.46M | 23.74K | 15.78K | 56.03M | 11.15M | 13.45M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3.52M | -1.21M | 2.32M | 0 | -190.55K | -6.76M | 0 | 0 |
| Net Change in Cash | 121.27K | -2.72M | 1.08M | -18.73M | 10.6M | 3.27M | 1.1M | 5.22M |
| Free Cash Flow | -11.45M | -13.39M | -14.49M | -28.72M | -20.66M | -11.02M | -10.62M | -8.23M |
| FCF Margin % | -173.74% | -24693.2% | -564.48% | -1010.51% | -307.36% | - | -258.99% | - |
| FCF Growth % | 19.74% | 7.57% | 49.54% | -38.99% | -87.44% | -3.81% | -29.09% | - |
| FCF per Share | -5.46 | -6.38 | -0.37 | -0.80 | -0.58 | -0.31 | -0.29 | -0.22 |
| FCF Conversion (FCF/Net Income) | 7.03x | 1.68x | 0.47x | 0.90x | 0.70x | 0.85x | 1.80x | 0.93x |
| Interest Paid | 159.89K | 0 | 569.77K | 283.04K | 126.66K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
According to the provided financial data, the company's operating cash flow consistently trails net income, with an OCF/NI ratio that reached -0.38 in 2026Q1, highlighting a persistent inability to convert accounting profits into actual liquidity as the firm remains in a deep pre-commercial development phase.
The divergence between net income and operating cash flow suggests that reported earnings are heavily influenced by non-cash items or accounting adjustments rather than operational performance. Investors should monitor this gap, as it indicates that the company's fundamental cash-generating capability remains non-existent despite occasional positive net income prints.
As reported in recent quarterly filings, HCWB's free cash flow trajectory remains deeply negative, with the company burning through approximately $1.6 million in 2026Q1 alone, underscoring a structural reliance on external financing to sustain its ongoing research and development activities without any offsetting commercial cash inflows.
The consistent negative free cash flow margins, which reached as low as -693.8% in 2025Q1, imply that the company is consuming capital at a rate that far exceeds its ability to generate internal funds. This trajectory suggests that the firm is entirely dependent on capital markets to maintain its clinical trial momentum.
Based on the reported figures, working capital changes have been highly erratic, swinging from a $10.0 million inflow in 2024Q2 to a $2.2 million outflow in 2025Q1, which suggests that the company's liquidity position is subject to significant, unpredictable fluctuations tied to its clinical development cycle.
These sharp swings in working capital appear to reflect the timing of research-related payments and grant receipts rather than efficient operational management. Such volatility warrants further investigation, as it complicates the predictability of the company's cash runway and overall financial stability.
As indicated by the cash flow statements, the company relies on stock-based compensation, which reached $292.1K in 2024Q4, to preserve cash, a practice that effectively masks the true cost of operations while simultaneously diluting existing shareholders to fund the firm's ongoing clinical research efforts.
While using equity to compensate personnel helps conserve limited cash reserves, it represents a significant hidden cost that is not fully captured in the operating cash flow. Investors should be wary of this reliance, as it may indicate that the company lacks the cash flow to attract talent through traditional salary structures.
Quick answers to the most common questions about buying HCWB stock.
HCW Biologics Inc. (HCWB) generated $-13.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
HCW Biologics Inc. (HCWB) reported negative free cash flow of $13.4M in 2025, indicating capital requirements exceeded cash from operations.
HCW Biologics Inc. (HCWB) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.